EW - Edwards Lifesciences hits new all-time high buoyed by strong Q1 results

Shares of Edwards Lifesciences (EW) hit an all-time high today after reporting Q1 earnings and revenue yesterday that beat analyst estimates.Non-GAAP EPS of $0.54 beat by $0.07, and revenue of $1.22B beat by $60M.Edwards also upped its full year 2021 adjusted EPS to $2.07 to $2.27 from $2.00 to $2.20. Consensus is $2.11.The company ended the quarter with $2.1B in cash.Edwards was helped in the quarter by the $792M in sales of its SAPIEN transcatheter aortic valve replacement ("TAVR") systems, which accounted for 65% of total sales.The company said the TAVR global market could exceed $7B by 2024, implying a compound annual growth rate in the low double digits.Edwards shares are up 5.4% to $94.45 in afternoon trading.

For further details see:

Edwards Lifesciences hits new all-time high buoyed by strong Q1 results